- Home
- GOSS vs IBIO Comparison
GOSS vs IBIO Comparison
Compare GOSS & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | IBIO |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 83.5M |
| IPO Year | 2018 | 2009 |
Fundamental Metrics
Financial Performance| Metric | GOSS | IBIO |
|---|---|---|
| Price | $0.16 | $1.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $4.19 | ★ $4.75 |
| AVG Volume (30 Days) | ★ 17.1M | 1.1M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $201.64 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.11 | $0.56 |
| 52 Week High | $3.87 | $3.82 |
Technical Indicators
Market Signals| Indicator | GOSS | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 34.54 |
| Support Level | $0.15 | $1.43 |
| Resistance Level | $0.20 | $1.80 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 56.40 | 3.62 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.